Entrada Therapeutics, Inc. TRDA
Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a neuromuscular/rare genetic drug developer. Its lead program, ENTR-601-44, is in Phase 2 for Duchenne muscular dystrophy (exon 44 skipping amenable). Its next catalyst on record is ENTR-601-44: Cohort 1 open-label data (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ENTR-601-44 — Cohort 1 open-label data (Q4 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ENTR-601-44 | DMD exon 44 skipping | oligonucleotide-other | Phase 2 |
| ENTR-601-45 | DMD exon 45 skipping | oligonucleotide-other | Phase 2 |
| VX-670 (partnered with Vertex) | Myotonic dystrophy type 1 (DM1) | oligonucleotide-other | Phase 2 |
| ENTR-601-50 | DMD exon 50 skipping | oligonucleotide-other | Phase 1 |
| ENTR-601-51 | DMD exon 51 skipping | oligonucleotide-other | Pre-clinical |
| ENTR-801 | Usher syndrome type 2A (USH2A) - exon 13 skipping amenable | oligonucleotide-other | Pre-clinical |
| Ocular program #2 (unnamed) | Inherited retinal disease (unspecified) | oligonucleotide-other | Pre-clinical |
Recent results and decisions
- Oct 31, 2026met ELEVATE-45-201 Cohort 1 reported in October 2026 met the primary objective of favorable safety and tolerability at an initial dose of 5 mg/kg.
Topline results met the primary objectives of favorable safety and tolerability.
Filing - Oct 31, 2026n/a U.S. FDA Office of Orphan Products Development granted orphan drug designation for ENTR-601-45 for the treatment of DMD.
In October 2026, the U.S. FDA Office of Orphan Products Development (OOPD) granted orphan drug designation for ENTR-601-45 for the treatment of DMD.
Filing - Oct 14, 2026positive Cohort 1 (5 mg/kg): favorable safety; mean dystrophin +0.10% (n=6, nominal p=0.03) vs -0.02% placebo; no functional benefit expected or observed.
A mean increase of 0.10% (n = 6, nominal p = 0.03) from baseline in dystrophin production was observed in study participants who received ENTR-601-45 versus a 0.02% mean decrease from baseline in study participants who received placebo
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.